Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.
Radford, John A
AffiliationDepartment of Pediatrics, Tufts University School of Medicine, Boston, MA, USA
MetadataShow full item record
AbstractWe developed a novel simulation model integrating multiple data sets to project long-term outcomes with contemporary therapy for early-stage Hodgkin lymphoma (ESHL), namely combined modality therapy (CMT) versus chemotherapy alone (CA) via 18 F-fluorodeoxyglucose positron emission tomography response-adaption. The model incorporated 3-year progression-free survival (PFS), probability of cure with/without relapse, frequency of severe late effects (LEs), and 35-year probability of LEs. Furthermore, we generated estimates for quality-adjusted life years (QALYs) and unadjusted survival (life years, LY) and used model projections to compare outcomes for CMTversusCA for two index patients. Patient 1: a 25-year-old male with favourable ESHL (stage IA); Patient 2: a 25-year-old female with unfavourable ESHL (stage IIB). Sensitivity analyses assessed the impact of alternative assumptions for LE probabilities. For Patient 1, CMT was superior to CA (CMT incremental gain = 0·11 QALYs, 0·21 LYs). For Patient 2, CA was superior to CMT (CA incremental gain = 0·37 QALYs, 0·92 LYs). For Patient 1, the advantage of CMT changed minimally when the proportion of severe LEs was reduced from 20% to 5% (0·15 QALYs, 0·43 LYs), whereas increasing the severity proportion for Patient 2's LEs from 20% to 80% enhanced the advantage of CA (1·1 QALYs, 6·5 LYs). Collectively, this detailed simulation model quantified the long-term impact that varied host factors and alternative contemporary treatments have in ESHL.
CitationEarly-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. 2018 Br J Haematol
JournalBritish Journal of Haematology
DescriptionLymphoma Research Team
- An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
- Authors: Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM, Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).
- Issue date: 2013 Dec
- Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
- Authors: Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N
- Issue date: 2015 Jan 9
- Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma.
- Authors: Torok JA, Wu Y, Chino J, Prosnitz LR, Beaven AW, Kim GJ, Kelsey CR
- Issue date: 2018 May
- Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
- Authors: King MT, Donaldson SS, Link MP, Natkunam Y, Advani RH, Hoppe RT
- Issue date: 2015 May 1
- Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.
- Authors: Iberri DJ, Hoppe RT, Advani RH
- Issue date: 2015 Sep